CA-ARMIS
22.1.2024 14:01:31 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape. The 2023 analysis of Armis’ proprietary data offers critical insight into the multifaceted challenges global organizations face when it comes to protecting the entire attack surface. Report findings serve as a blueprint to help security teams worldwide prioritize efforts to reduce cyber risk exposure in 2024.
The report found that global attack attempts more than doubled in 2023, increasing 104%. Utilities (over 200% increase) and Manufacturing (165% increase) were the most at risk industries. Attack attempts peaked in July, with communications devices, imaging devices and manufacturing devices experiencing intensified targeting during this period.
“Armis found that not only are attack attempts increasing, but cybersecurity blind spots and critical vulnerabilities are worsening, painting prime targets for malicious actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “It’s critical that security teams leverage similar intelligence defensively so that they know where to prioritize efforts and fill these gaps to mitigate risk. We hope that by sharing these insights, global businesses and governments will leverage them to immediately pinpoint what they should be focusing on to improve their cybersecurity posture this year to keep critical infrastructure, economies and society safe and secure.”
Key findings of The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape include:
Geopolitical tensions exacerbate the cybersecurity landscape
-
Cyberwarfare grew more widespread in 2023. Top industries exposed to attack from Chinese and Russian actors were those within Manufacturing, Educational Services and Public Administration.
- In manufacturing, .cn and .ru domains contributed to an average of 30% of monthly attack attempts, while attacks from these domains on Educational Services have risen to about 10% of total attacks.
Legacy technology steepens incline of cybersecurity pros’ existing up-hill battle
-
Older Windows server OS versions (2012 and earlier) are 77% more likely to experience attack attempts compared to newer Windows Server versions.
- This vulnerability is particularly evident in the server environment, with nearly a quarter of server versions facing end-of-support (EoS) scenarios. The Educational Services industry has a significantly higher percentage of servers (41%) with unpatched weaponized Common Vulnerabilities and Exposures (CVEs), compared to the general average of 10%.
- Industries still using end-of-life (EoL) or EoS OSs that are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer: Educational Services (18%), Retail (14%), Healthcare (12%), Manufacturing (11%) and Public Administration (10%).
Businesses struggle with effective vulnerability prioritization and remediation
- There were over 65,000 unique CVEs discovered in 2023.
- Wearable devices have the highest percentage (93%) of unpatched CVEs.
- A third of all devices are still not patched for Log4Shell.
-
Patch rates for critical CVEs are not prioritized:
- Low CVEs: 11% patch rate
- Medium CVEs: 58% patch rate
- High CVEs: 64% patch rate
- Critical CVEs: 55% patch rate
- Irrespective of the weaponization status of a CVE, organizations consistently grapple with patch rates at 62% for non-weaponized and 61% for weaponized vulnerabilities.
“Blueprints like this report are invaluable as they help teams focus limited resources on efforts with the greatest impact and with the insights to tell data-driven stories in justification of cross-team priorities,” said Curtis Simpson, CISO, Armis. “Using hindsight and analyzed data could allow CISOs to focus 2024 efforts on segmenting legacy technology, prioritizing exposures of greatest significance, and utilizing AI-driven technologies that can assist security teams with defending and managing the attack surface in real-time.”
Proprietary data leveraged for this report was mined from Armis’ Asset Intelligence Engine. The Armis Asset Intelligence Engine is a collective AI-powered knowledge base, monitoring billions of assets worldwide, in order to identify cyber risk patterns and behaviors. It feeds the Armis Centrix™ platform with unique, actionable cyber intelligence to detect and address real-time threats across the entire attack surface.
To read the full report, The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape, please visit: https://www.armis.com/anatomy-of-cybersecurity
Learn more about The Armis Asset Intelligence Engine here: https://www.armis.com/platform/armis-asset-intelligence-engine/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122998889/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
